MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity.
D000818:Animals; D000928:Antidepressive Agents / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D001643:Bridged Bicyclo Compounds / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D016466:CHO Cells; D006224:Cricetinae; D003863:Depression / Q000188:drug therapy / Q000378:metabolism; D003998:Dicarboxylic Acids / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D007398:Interpersonal Relations; D008124:Locomotion / Q000187:drug effects / Q000502:physiology; D008297:Male; D018782:Maze Learning / Q000187:drug effects / Q000502:physiology; D051379:Mice; D008813:Mice, Inbred ICR; D011485:Protein Binding / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D018094:Receptors, Metabotropic Glutamate / Q000037:antagonists & inhibitors* / Q000378:metabolism
C483757:2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo(3.1.0)hexane-2,6-dicarboxylic acid; D000928:Antidepressive Agents; D001643:Bridged Bicyclo Compounds; D003998:Dicarboxylic Acids; D018094:Receptors, Metabotropic Glutamate; C108822:metabotropic glutamate receptor 2